Summary
The effects of the tetrahydroisoquinoline alkaloids: tetrahydropapaveroline (THP) and salsolinol alone or in combination with psychopharmacological drugs on cerebral monoamine metabolism in the rat were studied.
-
1.
d,l-THP administered intraventricularly to rats in doses of 70\2-250 \gmg induced a sustained fall in striatal dopamine concentrations with a maximum depletion occurring at 3\2-6 h after drug administration. The striatal homovanillic acid (HVA) concentration was increased significantly at 3 h after THP administration.
Striatal 5-hydroxytryptamine (5-HT) and diencephalic noradrenaline or 5-HT levels were decreased following the THP administration.
THP was not found to induce any in vivo alterations in monoamineoxidase (MAO) or catechol-O-methyl transferase (COMT) activities in rat brain.
-
2.
Salsolinol (250 \gmg intraventricularly) caused a delayed rise in striatal dopamine concentration which at 6 h after the drug administration rose to about 3 times the control value. The effects of salsolinol on striatal HVA showed a fall 3 h after drug administration. Diencephalic noradrenaline and 5-HT concentrations were lower than controls 6 h after drug administration.
-
3.
In order to investigate the mechanisms underlying the biochemical effects of THP or salsolinol on brain catecholamines and 5-HT, psychopharmacological drugs were given to rats together with THP or salsolinol (250 \gmg intraventricularly).
Haloperidol (5 mg/kg, i.p.) pretreatment 45 min before THP partially prevented the striatal dopamine reduction and the HVA increase induced by THP alone; furthermore, haloperidol reversed the THP effect on diencephalic noradrenaline but not 5-HT.
Desmethylimipramine (25 mg/kg, i.p.) administered 45 min before THP prevented the THP induced depletions of the monoamines.
On the other hand, gamma-hydroxybutyrate pretreatments of the rats were not found to affect the THP induced alterations in catecholamines.
the salsolinol induced rise in striatal dopamine was prevented by α-methyl-p-tyrosine (300 mg/kg, i.p., administered twice in 24 h) pretreatment while the salsolinol induced fall in diencephalic noradrenaline was not affected.
Reserpine (5 mg/kg, s.c.) pretreatment of rats prevented the salsolinol induced rise in striatal dopamine and similarly haloperidol (5 mg/kg, i.p.) affected the dopamine but not the noradrenaline changes caused by salsolinol.
-
4.
For the mode of action of THP it is likely that the alkaloid is taken up in catecholaminergic, and possibly to a small extent serotonergic, neurones and thereby displacing dopamine or noradrenaline from storage sites. THP or a metabolite may act as a false transmitter and/or affecting catecholaminergic receptors directly and independently of a presynaptic release.
THP and salsolinol appear to have some basic differences in their mode of action on dopaminergic, but probably not on noradrenergic, mechanisms. For salsolinol the concept of a false transmitter seems most unlikely for the effect on dopaminergic neurones and, in fact, it may be that salsolinol in addition to actually causing increased synthesis of dopamine, has agonistic, while THP has antagonistic, properties in acting on dopamine receptors.
-
5.
Salsolinol was found to cause hypothermia while THP caused hyperthermia in the rat.
THP and salsolinol induced abnormal motor behaviour in rats in the form of gnawing, licking, chewing, head-neck rocking and increased motor activity and the motor dysfunctions were most apparent for THP. These dyskinetic phenomena are discussed briefly in relation to dopaminergic mechanisms.
Similar content being viewed by others
References
Ahtee, L., Sharman, D. F., Vogt, M.: Acid metabolites of monoamines in avian brain; effect of probenecid and reserpine. Br. J. Pharmacol. 38, 72–85 (1970)
Alpers, H. S., McLaughlin, B. R., Nix, W. M., Davis, V. E.: Inhibition of catecholamine uptake and retention in synaptosomal preparations by tetrahydroisoquinoline and tetrahydroprotoberberine alkaloids. Biochem. Pharmacol. 24, 1391–1396 (1975)
Andén, N.-E.: Physiology and pharmacology of the nigroneostriatal dopamine neurones. In: Progress in Neurogenetics (A. Barbeau and J. R. Brunette, eds.), p. 265. Amsterdam: Excerpta Medica Foundation 1969.
Anton, A. H., Sayre, D. F.: The distribution of dopamine and dopa in various animals and a method for their determination in diverse biological material. J. Pharmacol. Exp. Ther. 145, 326–336 (1965)
Bertler, Å.: Effect of reserpine on the storage of catecholamines in brain and other tissues. Acta Physiol. Scand. 51, 75–83 (1961)
Broch, O. J., Guldberg, H. C.: On the determination of catechol-O-methyltransferase activity in tissue homogenates. Acta Pharmacol. Toxicol. (Kbh.) 30, 266–277 (1971)
Brezenoff, M. E., Cohen, G.: Hypothermia following intraventricular injection of a dopamine-derived tetrahydroisoquinoline alkaloid. Neuropharmacology 12, 1033–1038 (1973)
Butcher, L. L., Engel, J.: Behavioural and biochemical effects of l-Dopa after peripheral decarboxylase inhibition. Brain Res. 15, 233–242 (1969)
Carlsson, A.: Morphologic and dynamic aspects of dopamine in the central nervous system. In: Biochemistry and pharmacology of the basal ganglia (E. Costa, L. J. Cote and M. C. Yahr, eds.), pp. 107–123. New York: Raven Press 1966
Cohen, G.: Tetrahydroisoquinoline alkaloids: uptake, storage and secretion by the adrenal medulla and by adrenergic nerves. Ann. N.Y. Acad. Sci. 215, 116–119 (1973)
Cohen, G., Katz, S.: 6,7-dihydroxytetrahydroisoquinoline: evidence for in vivo inhibition of intraneuronal monoamine oxidase. J. Neurochem. 25, 719–722 (1975)
Cohen, G., Heikkila, R. E., Dembiec, D., Sang, D., Teitel, S., Brossi, A.: Pharmacologic activity of stereoisomers of 1-substituted 6,7-dihydroxyisoquinolines inhibition of 3H-dopamine accumulation by rat brain slices and lipolytic activity with isolated mouse fat cells. Eur. J. Pharmacol. 29, 292–297 (1974)
Cohen, G., Mytillineou, C., Barrett, R.: 6,7-dihydroxytetrahydroisoquinoline — uptake and storage by peripheral sympathetic nerve of rat. Science 175, 1269–1272 (1972)
Collins, A. C., Cashaw, J. L., Davis, V. E.: Dopamine-derived tetrahydroisoquinoline alkaloids, inhibitors of monoamine metabolism. Biochem. Pharmacol. 22, 2337–2348 (1973)
Collins, M. A., Bigdeli, M. G.: Tetrahydroisoquinolines in vivo. I. Rat brain formation of salsolinol, a condensation product of dopamine and acetaldehyde, under certain conditions during ethanol intoxication. Life Sci. 16, 585–601 (1975)
Costall, B., Naylor, R. J., Pinder, R. M.: Dyskinetic phenomena caused by the intrastriatal injection of phenylethylamine, phenyl-piperazine, tetrahydroisoquinoline and tetrahydronaphthalene derivates in the guinea pig. Eur. J. Pharmacol. 31, 94–109 (1975)
Davis, V. E., Walsh, M. J.: Alcohol, amines and alkaloids: A possible biochemical basis for alcohol addiction. Science 167, 1005–1007 (1970)
Dougan, D., Wase, D., Mearrick, P.: Effects of l-Dopa metabolites at a dopamine receptor suggest a basis for “on-off” effect in Parkinson's Disease. Nature (Lond.), 254, 70–73 (1975)
Ernst, A. M.: Relation between the action of dopamine and apomorphine and their O-methylated derivatives upon the CNS. Psychopharmacology 7, 391–399 (1965)
Feller, D. R., Venktraman, R., Miller, D. D.: Comparative actions of trimetoquinal, tetrahydropapaverdine and salsolinol isomers in β-adrenoceptor systems. Biochem. Pharmacol. 24, 1357–1359 (1975)
Giovine, A., Renis, M., Bertolino, A.: In vivo and in vitro studies on the effect of tetrahydropapaveroline and salsolinol on COMT and MAO activity in rat brain. Pharmacology 14, 86–94 (1976)
Glowinski, J., Axelrod, J., Iversen, L. L.: Regional studies of catecholamines in rat brain IV: Effects of drugs on the disposition and metabolism of 3H-norepinephrine and 3H-dopamine. J. Pharmacol. Exp. Ther. 153, 30–39 (1966)
Guldberg, H. C., Marsden, C. A.: Catechol-O-methyltransferase: pharmacological aspects and physiological role. Pharmacol. Rev. 27, 135–206 (1975)
Heikkila, R., Cohen, G., Dembiec, D.: Tetrahydroisoquinoline alkaloids: Uptake by rat brain homogenates and inhibition of catecholamine uptake. J. Pharmacol. Exp. Ther. 179, 250–258 (1971)
Hjort, A. M., DeBeer, E. J., Buck, J. S., Randall, L. O.: Relative pharmacological effects of 1-methyl-3,4-dihydro and 1-methyl-1,2,3,4-tetrahydroisoquinoline derivatives. J. Pharmacol. Exp. Ther. 76, 263–269 (1942)
Häggendal, J., Lindqvist, M.: Disclosure of labile monoamine fractions in brain and their correlation to behaviour. Acta Physiol. Scand. 60, 351 (1964)
Hornykiewicz, O.: The mechanisms of action of l-Dopa in Parkinson's disease. Life Sci. 15, 1249–1259 (1974)
Juorio, A. V., Sharman, D. F., Trajkov, T.: The effect of drugs on the homovanillic acid content of the corpus striatum of some rodents. Br. J. Pharmacol. 26, 385–392 (1966)
Livrea, P., Leda, L. D., Giovine, A., Bercolino, A.: Effects of tetrahydropapaveroline on dopamine and 5-hydroxytryptamine metabolism in rat brain in vivo. Pharmacology 14, 20–26 (1976)
Locke, S., Cohen, G., Dembiec, D.: Uptake and accumulation of 3H-6,7-dihydroxytetrahydroisoquinoline by peripheral sympathetic nerves in vivo. J. Pharmacol. Exp. Ther. 187, 56–67 (1973)
Lorens, S. A., Guldberg, H. C.: Regional 5-hydroxytryptamine following selective midbrain raphe lesions in the rat. Brain Res. 78, 45–56 (1974)
Menon, M. K., Fleming, R. M., Clark, W. G.: Studies on the biochemical mechanisms of the central effect of gammahydroxybutyric acid. Biochem. Pharmacol. 23, 879–885 (1974)
Miller, R., Horn, A., Iversen, L. L.: Effect of dopamine-like drugs on rat striatal adenyl cyclase have implications for CNS dopamine receptor topography. Nature (Lond.) 250, 238–241 (1974)
Mytillineou, C., Cohen, G., Barret, R.: Tetrahydroisoquinoline alkaloids: uptake and release by adrenergic nerves in vivo. Eur. J. Pharmacol. 25, 390–401 (1974)
Nybäck, J., Borzeckl, Z., Sedvall, G.: Accumulation and disappearance of catecholamines formed from tyrosine-14C in mouse brain: effect of some psychotropic drugs. Eur. J. Pharmacol. 4, 395–403 (1968)
Pyman, F. L.: CLXXXII-isoquinoline derivatives. Part II. The constitution of the reduction products of papaverine. J. Chem. Soc. 95, 1610–1623 (1909)
Roth, R. H., Suhr, Y.: Mechanisms of the gamma-hydroxybutyrate-induced increase in brain dopamine and its relationship to “sleep”. Biochem. Pharmacol. 19, 3001–3012 (1970)
Rubenstein, J. A., Collins, M. A.: Tetrahydroisoquinolines derived from noradrenaline-aldehyde condensation. Pyrogallolsensitive O-methylation in rat homogenates. Biochem. Pharmacol. 22, 2928–2931 (1973)
Sandler, M., Carter, S. B., Hunter, K. H., Stern, G. M.: Tetrahydroisoquinoline alkaloids: in vivo metabolites of l-Dopa in man. Nature (Lond.) 241, 439–443 (1973)
Santi, R., Ferrari, M., Tóth, C. E., Contessa, A. R., Fassina, G., Bruni, A., Luciani, S.: Pharmacological properties of tetrahydropapaveroline. J. Pharm. Pharmacol. 19, 41–51 (1967)
Sheppard, H., Burghardt, C. R.: Effect of tetrahydroisoquinoline derivatives on the adenylate cyclases of the caudate nucleus (dopamine type) and erythrocyte (β-type) of the rat. Res. Communication in Chem. Path. Pharmacol. 8, 527–534 (1974)
Simpson, L. L.: An analysis of the sympathomimetric activity of 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (TIQ). J. Pharmacol. Exp. Ther. 192, 365–371 (1975)
Snyder, S. H., Hendley, E. D.: A simple and sensitive fluorescence assay for monoamine oxidase and diamine oxidase. J. Pharmacol. Exp. Ther. 163, 386–392 (1968)
Sourkes, T. L.: Possible new metabolites mediating actions of l-Dopa. Nature (Lond.) 229, 413–414 (1971)
Tennyson, V. M., Cohen, G., Mytillineou, C., Heikkila, R.: 6,7-dihydroxytetraisoquinoline: electron microscopic evidence for uptake into the amine-binding vesicles in sympathetic nerves of rat iris and pineal gland. Brain Res. 51, 161–169 (1973)
Trepanier, D. L., Sunder, S.: 3,4-dihydroisocarbostyril and 1,2,3,4-tetrahydroisoquinoline derivatives of ephedrine. J. Med. Chem. 16, 342–347 (1973)
Turner, A. J., Baker, K. M., Algeri, S., Frigerio, A., Garattini, S.: Tetrahydropapaveroline: formation in vivo and in vitro. Life Sci. 14, 2247–2257 (1974)
Walters, J. R., Roth, R. H.: Effect of gamma-hydroxybutyrate on dopamine metabolites in the rat striatum. Biochem. Pharmacol. 21, 2111–2121 (1972)
Yamanaka, Y., Walsh, M. J., Davis, V. E.: Salsolinol: an alkaloid derivative of dopamine formed in vitro during alcohol metabolism. Nature (Lond.) 227, 1143–1144 (1970)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Awazi, N., Guldberg, H.C. Effects of tetrahydropapaveroline and salsolinol on cerebral monoamine metabolism and their interactions with psychopharmacological drugs. Naunyn-Schmiedeberg's Arch. Pharmacol. 306, 135–146 (1979). https://doi.org/10.1007/BF00498983
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00498983